


Figure 1A



Encapsulated Dox (MFI)
80
60
40
20
0
Dox (MFI)
DiI5 (MFI)
10
3
0
Trastuzumab (μg/mL)
2000
1500
1000
500
0
Lipid DiI5 (MFI)

Figure 1B



0.1 µg/mL MM-302
1µM trastuzumab
p < 0.01
p < 0.001
Viability at 96 hr
% of untreated
120
100
80
60
40
20
0
untreated
MM-302 only
trastuzumab only
MM-302 + trastuzumab

Figure 2A



Combi divided by best single agent
0.5
0.75
1
1.25
MCF7 (clone18)
HCC1954
OE33
JIMT1
HCC202
UACC812
HCC2218
MDA-MB-453
SUM190
CaLu3
ZR75-30
U251
OVCAR8-HER2
A549
HeLa-9VH1
AdrR-HER2
HCC1419
BT474-M3
MDA-MB-361
HCC1569
SKOV3
BT474-HRG
BT474-(clone4)
SKBR3
NCI-N87-HRG
BT474-(PTEN)
OE19
AU565
NCI-N87

Figure 2B



Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
Days after inoculation
CTL
MM-302 6 mg/kg
MM-302 3 mg/kg
UT-PLD 6 mg/kg
UT-PLD 3 mg/kg
Tumor Volume (mm3)
3500
3000
2500
2000
1500
1000
500
0
0
20
30
40
50
60
Days after inoculation
CTL
MM-302 3mg/kg
UT-PLD 3mg/kg
Free DOX 3mg/kg

Figure 3A



Tumor Volume (mm3)
1200
1000
800
600
400
200
0
0
10
20
30
40
50
60
Days after inoculation
CTL
MM-302 6mg/kg
MM-302 3mg/kg
UT-PLD 6mg/kg
UT-PLD 3mg/kg
Tumore volume (mm3)
1000
800
600
400
200
0
20
30
40
50
60
70
Days after inoculation
CTL
MM-302 3mg/kg
UT-PLD 3mg/kg
Free DOX 3mg/kg

Figure 3B



CTL
trastuzumab 3.5 mg/kg q3d
MM-302 3 mg/kg weekly
MM-302 & trastuzumab
Tumor Volume (mm3)
Days after Inoculation
CTL
trastuzumab 3.5mg/kg q3d
MM-302 3mg/kg weekly
MM-302 3 & trastuzumab
Tumor Volume (mm3)
Days after inoculation

Figure 3C



Anthracycline Naïve
N 9
CR 1
PR 3
SD 1
ORR 44%
CBR 56%
Best change in tumor burden
(% change)
100
75
50
25
0
-25
-50
-75
-100
500-1009
200-1022
300-1013
500-1019
100-1024
100-1027
100-1010
500-1018
200-1033

Figure 4A



Anthracycline Exposed
Best change in tumor burden
(% change)
N 18
CR 0
PR 0
SD 5
ORR 0%
CBR 28%
500-1011
200-1026
300-1032
100-1021
300-1030
100-1028
200-1023
100-1017
500-1031
300-1034
500-1016
300-1029
300-1012
100-1025
500-1020

Figure 4B



PFS: 10.9 months
(95% CI: 1.6, NR)
Anthracycline Naïve
500-1009
200-1022
300-1013
500-1019
100-1024
100-1027
100-1010
500-1018
200-1033
0
6
12
Progression-free survival (PFS)
(months)

Figure 4C



Anthracycline Exposed
PFS: 5.6 months
(95% CI: 1.9, 8.6)
500-1020
100-1025
300-1012
300-1029
500-1016
300-1034
500-1031
100-1017
200-1023
100-1028
300-1030
100-1021
300-1032
200-1026
500-1011
Progression-free survival (PFS)
(months)

Figure 4D



Anthracycline Naive
Off Study
On Study
100
75
50
25
0
-25
-50
-75
-100
best change in tumor volume
(% change)
100-1040
500-1038
200-1036
500-1045

Figure 5A



Anthracycline Exposed
Off Study
On Study
100
75
50
25
0
-25
-50
-75
-100
best change in tumor volume
(% change)
100-1041
300-1037
500-1043
200-1039
500-1042
100-1044

Figure 5B



progression free survival
(months)
0
6
12
Off Study
On Study
100-1040
500-1038
200-1036
500-1045

Figure 5C




progression free survival
(months)
0
6
12
Off Study
On Study
100-1041
300-1037
500-1043
200-1039
500-1042
100-1044

Figure 5D



MM-302					Total cumulative doxorubicin (mg/m²)	Prior doxorubicin (mg/m²)	MM-302 received (mg/m²)
					32		32
	8 mg/m²				16		16
					32		32
					32		32
	16 mg/m²				16		16
					48		48
					16		16
					32		32
	30 mg/m²				375		375
					60		60
					291	231	60
	40 mg/m²				520	240	280
					480		480
					320	240	80
					520*		520*
					720	240	480
					280	240	40
					600*		600*
					360	280	80
					400		400
					720	240	480
					370	290	80
					160		160
	50 mg/m²				370	120	250
					510	240	270
					450	300	150
					100		100
					340	240	100
					610	240	370
					340	240	100
					638	238	400
					140	40	100
					100		100
					485	335	150
					420	240	180
+ HERCEPTIN	30 mg/m²				330*		330*
					360	240	120
					240*		240*
					349	251	98
					60		60
					455	402	53
	40 mg/m²				470*	270	200*
					400	240	160
					310	230	80
					200*		200*
	30 mg/m²				330*	240	90*
					60*		60*
					360*	300	60*

Figure 6